Transparency Market Research

Peptide Therapeutics Market Expected to Reach USD 23.7 Billion Globally in 2020

Peptide Therapeutics Market (by Applications, by Route of Administration, and by Marketing Status) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 – 2020


Albany, NY -- (SBWIRE) -- 07/08/2015 -- According to a new market report published by Transparency Market Research "Peptide Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020," the global peptide therapeutics market was valued at USD 18.9 billion in 2013 and is estimated to reach USD 23.7 billion by 2020 at a CAGR of 2.8% from 2014 to 2020.

Browse the full Peptide Therapeutics Market Report at

Therapeutic peptides have been approved for various indications including metabolic disorders, hematological disorders, cancer, cardiovascular disorders, central nervous system disorders, infection, gastrointestinal disorders, respiratory disorders, acromegaly, and others. Such diverse areas of application dictate efficiency of peptides in medical treatment. Increasing research and development activities towards exploration of novel peptides with better therapeutic effect has resulted in a rich pipeline. Animal sources such as venom have been major sources of peptides for research. Scientists are also trying various microbial sources for discovery of novel peptides with therapeutic effect. Despite extensive research efforts, oral delivery of therapeutic peptides or proteins is still a challenge for researchers, due to unfavorable physiological conditions such as acidic pH and presence of proteolytic enzymes. Moreover, low permeability of peptides across the intestinal barrier is a factor adding to the low bioavailability.


Since 2001, over 19 new therapeutic peptides have been approved in the U.S., of these eight were approved in 2012, according to a review article published in the Drug Discovery Today. While new peptide drugs receive regulatory clearance, several peptide drugs are also expected to go off-patent during the forecast period. Generic manufacturers face difficulties in drug approval, as biologics are hard to mimic. Increased costs have driven players to quit research and development activities. This is also a reason why generic peptide drugs retain over 70% to 80% of the branded drug's price. Due to such high price of generic drugs, peptide therapeutics market is expected to grow rapidly post approval of generic versions. Generic leuprolide is marketed under brand names Enantone, Eligard, and Lupron; of which Enantone and Lupron recorded sales of more than USD 800 million globally.

Currently, Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Co. Ltd. and Novo Nordisk account for over 50% of the global peptide therapeutics market share. Patent expiry of Copaxone in 2014, and Velcade in 2017 and expected launch of their generic alternatives may alter the market trend. Other key players in the market include AstraZeneca plc, Novartis International AG, Eli Lilly & Co., AbbVie, Inc. and Merck & Co.

Browse Full Press Release Report:

The global peptide therapeutics market has been segmented as below:
Global Peptide Therapeutics Market, by Application
Zoladex (goserelin)
Velcade (bortezomib)
Lupron/ Enantone/ Eligard (leuprorelin)
Angiomax (bivalirudin)
Integrilin (eptifibatide)
Central Nervous System
Copaxone (glatiramer)
Metabolic Disorders
Victoza (liraglutide)
Byetta (exenatide)
Incivek (telaprevir)
Victrelis (boceprevir)
Hematological Disorders
Firazyr (icatibant)
Kalbitor (ecallantide)
Gastrointestinal Disorders
Gattex (teduglutide)
Linzess (linaclotide)
Respiratory Disorders
Other Applications
Global Peptide Therapeutics Market, by Route of Administration
Global Peptide Therapeutics Market, by Marketing Status
Global Peptide Therapeutics Market, by Geography
North America
Asia Pacific
Rest of the World

Request a Brochure of this Report:

About Transparency Market Research
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We have an experienced team of Analysts, Researchers, and Consultants, who use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR Syndicated Research report covers a different sector — such as pharmaceuticals, chemical, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, our syndicated reports thrive to provide clients to serve their overall research requirement.

Mr. Nachiket Ghumare
90 State Street, Suite 700
Albany, NY 12207
Tel: 518-618-1030
USA - Canada Toll Free: 866-552-3453